MedTrace Logo

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00308243 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-07-19

No results posted yet for this study

Summary

It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and nitrogen compounds associated with the chronic inflammatory component of the disease. The primary objective of the study is to assess the safety of inhaled sodium pyruvate in 0.9% sodium chloride (saline) solution in people with CF. Further, to determine whether inhaled sodium pyruvate will improve lung function, as determined by spirometry, or reduced inflammatory markers in induced sputum of people with CF.

Conditions

Interventions

DRUG

Sodium Pyruvate in 0.9% Sodium Chloride Solution

Sponsors & Collaborators

  • Cellular Sciences, inc.

    collaborator INDUSTRY

  • Emphycorp

    lead INDUSTRY

Principal Investigators

  • Joanne Billings, MD · University of Minnesota; Pulmonary, Allergy & Critical Care Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308243 on ClinicalTrials.gov